AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD. |
On March21, 2017, Audentes Therapeutics, Inc. (Company) entered
into an amendment to the Exclusive License and Collaboration
Agreement, dated May3, 2016, by and between the Company and The
Trustees of the University of Pennsylvania. A copy of the
amendment is filed herewith as Exhibit 10.01.
| Item9.01 | Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
|
| 10.01 |
Second Amendment to Exclusive License and Collaboration Agreement, dated March21, 2017, by and between the Company and The Trustees of the University of Pennsylvania. |
|
The Company has omitted and filed separately with the SEC portions of the exhibit to a confidential treatment request under Rule 24b-2 promulgated under the Exchange Act. |
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| AUDENTES THERAPEUTICS, INC. | ||||||
|
Date: April3, 2017 |
By: |
/s/ Thomas Soloway |
||||
| Thomas Soloway | ||||||
| Chief Financial Officer |
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
| 10.01 |
Second Amendment to Exclusive License and Collaboration Agreement, dated March21, 2017, by and between the Company and The Trustees of the University of Pennsylvania. |
|
The Company has omitted and filed separately with the SEC portions of the exhibit |
About AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD)
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues. AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Recent Trading Information
AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) closed its last trading session down -0.21 at 16.83 with 94,945 shares trading hands.
